Popova, Vjara
Kissling, Seraphina
Micheroli, Raphael
Bräm, René
de Hooge, Manouk
Baraliakos, Xenofon
Nissen, Michael J.
Möller, Burkhard
Exer, Pascale
Andor, Michael
Distler, Oliver
Scherer, Almut
Ospelt, Caroline
Ciurea, Adrian
Article History
Received: 15 December 2022
Accepted: 6 March 2023
First Online: 13 March 2023
Declarations
:
: The ethics committee of the Canton of Zurich (KEK-ZH-Nr. 2014–0439 and BASEC 2022–00272) approved the study. Written informed consent was obtained from all patients prior to inclusion into SCQM.
: Not applicable.
: The SCQM foundation is supported by the Swiss Society of Rheumatology and by Abbvie, Biogen, iQone, Janssen, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Samsung Bioepis, Sandoz. AC received honoraria for lectures or presentations from AbbVie, Merck Sharp & Dohme and Novartis and is ASAS/EULAR taskforce member. AS received consulting fees from Pfizer and support for attending meetings from Gilead. BM received speaking fees from Jansen, Eli Lilly, Novartis and Pfizer, support for attending meetings from Janssen and Pfizer and a research grant from Celgene. MdH received grants from FWRO/FRSR and honoraria from UCB for participation in advisory board. She is member of the EULAR advocacy committee, young ASAS leader and ASAS-EULAR taskforce member. MJN received consulting and/or speaking fees from Abbvie, Eli Lilly, Janssen, Novartis and Pfizer and a research grant from Novartis. He is ASAS-EULAR taskforce member and a scientific member of the SCQM registry and the EuroSpA collaboration. OD received consulting fees from Abbvie. PE received financial support from UCB for attending a meeting. RM received honoraria for lectures or presentations from Abbvie, Eli Lilly, Janssen, Gilead and Pfizer. CO, MA, RB, SK, VP, and XB declare they have no conflicts of interest.